Shares of Biogen (BIIB) jumped by a staggering 43.08% in 30 days from $277.22 to $396.64 at 20:12 EST on Friday, after two successive sessions in a row of gains. NASDAQ Composite (BIIB) is rising 0.35% to $14,069.42, following the last session’s upward trend.

Biogen’s last close was $414.71, 11.49% under its 52-week high of $468.55.


Today’s last reported volume for Biogen is 4217513 which is 152.69% above its average volume of 1669034.

The company’s growth estimates for the ongoing quarter and the next is a negative 54.7% and a negative 48.8%, respectively.

Biogen’s Revenue

Year-on-year quarterly revenue growth declined by 23.8%, now sitting on 12.6B for the twelve trailing months.


Biogen’s last week, last month’s, and last quarter’s current volatility was 13.72%, 2.20%, and 1.83%, respectively.

Biogen’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 13.80% (last week), 3.14% (last month), and 1.83% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Biogen’s stock is considered to be oversold (<=20).

Biogen’s Stock Yearly Top and Bottom Value

Biogen’s stock is valued at $396.64 at 20:12 EST, way under its 52-week high of $468.55 and way above its 52-week low of $223.25.

Biogen’s Moving Average

Biogen’s value is way above its 50-day moving average of $288.25 and way above its 200-day moving average of $269.66.

Previous days news about Biogen (BIIB)

Biogen alzheimer’s drug won’t break bank right away: CVS CEO. According to Bloomberg Quint on Wednesday, 9 June, "Cigna is in talks with Biogen on developing a value-based contract for Aduhelm, the companies said after the drug was approved."

Biogen gets an unearned rip on an unproven drug. According to InvestorPlace on Thursday, 10 June, "Nevertheless, Biogen now has over $20 billion in new market cap it can invest in buying other drug companies or new drugs. ", "While Biogen is up 61% since the FDA decision, the SPDR S&P Biotech ETF (NYSEARCA:XBI) is up just 5%. "

Harvard expert quits FDA panel as biogen drug furor grows. According to Bloomberg Quint on Thursday, 10 June, "A prominent Harvard Medical School professor has resigned from a U.S. Food and Drug Administration advisory panel in protest over the agency’s decision to approve Biogen Inc.’s Alzheimer’s drug Aduhelm."

Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains. According to MarketWatch on Friday, 11 June, "Shares of Biogen Inc. dropped 4.1% in afternoon trading Friday, to pull back from a six-year high, but UBS analyst Colin Bristow seems room for further gains to a record close. "

More news about Biogen (BIIB).


Please enter your comment!
Please enter your name here